ReviewActa bio-medica : Atenei Parmensis2019
Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature.
Review in Acta bio-medica : Atenei Parmensis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Height benefits after GnRHa treatment in girls aged over 6 years with central precocious puberty: a meta-analysis.Endocrine · 2025Pooled it
- Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- Is surgery effective for treating hypothalamic hamartoma causing isolated central precocious puberty? A systematic review.Neurosurgical review · 2021Pooled it
- The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys.BMC pediatrics · 2025Trial
- The therapeutic role and potential mechanism of EGCG in obesity-related precocious puberty as determined by integrated metabolomics and network pharmacology.Frontiers in endocrinology · 2023Trial
- Comparative efficacy of quarterly vs. monthly triptorelin in Chinese girls with central precocious puberty: a 12-month observational study.Frontiers in pediatrics · 2026Article
- Outcomes of GnRH Agonist Therapy in Boys with Central Precocious Puberty: A Systematic Review of Final Height and Long-Term Health Effects.International journal of preventive medicine · 2026Review
- Polycystic ovary syndrome and idiopathic central precocious puberty: two sides of the same coin?Endocrine · 2025Review
- Final Adult Height in Girls Treated with GnRH Analogues for Precocious Puberty Around Age Eight.Children (Basel, Switzerland) · 2025Article
- Article
- The Effect of GnRH Analogs on Body Mass Index in Girls with Central Precocious Puberty: A Single-Center Retrospective Study with a Literature Review.Children (Basel, Switzerland) · 2025Article
- Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis.Hormone research in paediatrics · 2025Article
- Exploring the molecular mechanism of EGCG in preventing obesity-induced precocious puberty based on serum metabolomics and molecular docking.Frontiers in nutrition · 2025Article
- Effects of Different Gonadotropin-Releasing Hormone Agonists on IVF/ICSI-ET Outcomes in Long Protocol: A Retrospective Study.International journal of women's health · 2025Article
- Childhood Obesity, Hypothalamic Inflammation, and the Onset of Puberty: A Narrative Review.Nutrients · 2024Review
- Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty.Pediatric research · 2024Observational
- [Considerations on the improvement of height benefit in children with central precocious puberty].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Global production and research trends on precocious puberty in the Web of Science database from 2000 to 2023: A bibliometric approach.Pediatric endocrinology, diabetes, and metabolism · 2024Article
- Pain mechanisms in the transgender individual: a review.Frontiers in pain research (Lausanne, Switzerland) · 2024Review
- 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents.Annals of pediatric endocrinology & metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central precocious puberty (CPP) is defined as an early pubertal development that occurs before the age of 9 years in boys and 8 years in girls. It results from premature activation of the hypothalamic-pituitary-gonadal axis. Gonadotropin-releasing hormone agonists (GnRHa) have been the gold standard therapy for CPP for more than 30 years. These compounds have a high affinity for the pituitary LHRH receptor and are resistant to enzymatic degradation. Through continuous stimulation, GnRHa inhibit the pulsatile secretion of gonadotropin, resulting in hormonal suppression, cessation of pubertal development, and normalization of growth and skeletal maturation rates. The goal of therapy is to halt pubertal progression and delay epiphyseal maturation that leads to improvement of final adult height. There are no widely accepted guidelines for how long to continue treatment with a GnRHa for CPP, and individual practice varies widely. Furthermore, conflicting results have been published on the long-term effects of GnRHa therapy in patients with CPP. Therefore, we reviewed the current literature focusing our attention on the long-term effects and the significant adverse drug reactions (ADRs) observed during treatment with GnRHa in patients with CPP. Our review may provide the necessary data to enable clinicians to administer GnRHa in the safest and most appropriate way. Further studies are necessary to identify the mechanisms of development of potential adverse drug reactions related to GnRHa therapy in CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.